Phase 2 N=176 Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients
Trichuris Infection · Helminthiasis
Primary: Cure Rate — 1; 31; 6; 40 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=4 Mucosal Immunity of Ulcerative Colitis Patients Undergoing Therapy With Trichuris Suis Ova
Ulcerative Colitis
Primary: Change From Baseline of Mucus Production at 12 Weeks and 24 Weeks as Assessed by Histopathology
Phase 2 N=250 Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Crohn's Disease
Primary: Evaluate the Effects of TSO on the Induction of Response in Crohn's Disease, as Measured Primarily by Crohn's Disease Activity Index (CDAI) — 55; 58 Participants
Phase 1 N=36 Safety and Tolerability of Single Doses Oral CNDO 201 Trichuris Suis Ova in Patients With Crohn's Disease
Crohn's Disease
Primary: Incidence of Adverse Events — 7; 4; 1; 7 events
N/A N=89,132 Comparative Effectiveness of Treatment Options for Genital Herpes Infection to Reduce Adverse Pregnancy Outcomes
HSV-2 Infection · PreTerm Birth · Pregnancy Complications
Primary: Number of Participants With Preterm Delivery — 100; 83; 247; 5407 Participants
Phase 2 N=229 Combination Therapy for Chronic Hepatitis C Infection
Hepatitis C, Chronic
Primary: The Proportion of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 100; 95; 95; 91.2 percentage of subjects
N/A N=52 A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial
Trachoma
Primary: The Proportion of Communities With C. Trachomatis Infection Prevalence of 1% or Below — 7; 4 community — p=>0.05
Phase 2 N=260 Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC
Trichuriasis · Ascariasis · Hookworm Infections
Primary: Cure Rate (CR) Against T. Trichiura — 17.5; 50.0; 83.3; 84.6 percentage of participants cured (%)
Phase 3 N=224 Efficacy and Safety of Moxidectin-Albendazole Co-administration in SAC
Trichuriasis · Ascariasis · Hookworm Infections
Primary: Cure Rate (CR) Against T. Trichiura — 69.4; 16.2; 11.8 percentage of participants cured (%)
Phase 3 N=95 Ethanol Lock Therapy for Treatment and Secondary Prophylaxis of Central Line-Associated Bloodstream Infection
Central Line-Associated Bloodstream Infection
Primary: Percentage of Therapeutic Failures (Early or Late Failure) in Children and Adolescents With CLABSI Receiving Standard Care Plus Ethanol Lock Therapy (ELT) vs. Standard…
Phase 2 N=15 Enhancement by Poly-ICLC During HIV-1 Infection
HIV-1 Infected Adults With Chronic HIV-1 Infection
Primary: Number Participants With Adverse Events — 11; 3 Participants
N/A N=300 Supplemental Oxygen Reduces Surgical Infection
Wound Infection
Primary: Incisional Surgical Wound Infection — 22; 35 participants — p=0.04
N/A N=120 HIV And Parasitic Infection (HAPI) Study
HIV Coinfection
Primary: Number of Participants With and Without Intestinal Parasitic Infection — 36; 84 Participants
Phase 3 N=1,676 Using BCG to Protect Senior Citizens During the COVID-19 Pandemic
Covid19 · Non-specific Effects of Vaccines · Heterologous Immunity
Primary: Acute Infection — 424; 469; 212; 236 Events — p=< 0.05
Phase 2 N=29 Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)
Cystic Fibrosis
Primary: Number of Patients MRSA Free by Induced Sputum Respiratory Tract Culture — 2; 3 Participants